Nada Stefanovic Selected Research

Atherosclerosis

1/2021	Specific NLRP3 Inhibition Protects Against Diabetes-Associated Atherosclerosis.
11/2016	Corrigendum to "Plasmalogen modulation attenuates atherosclerosis in ApoE- and ApoE/GPx1-deficient mice" [Atherosclerosis 243/2 (2015) 598-608].
4/2016	Lack of glutathione peroxidase-1 facilitates a pro-inflammatory and activated vascular endothelium.
12/2015	Plasmalogen modulation attenuates atherosclerosis in ApoE- and ApoE/GPx1-deficient mice.
11/2015	Direct Endothelial Nitric Oxide Synthase Activation Provides Atheroprotection in Diabetes-Accelerated Atherosclerosis.
9/2014	Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease.
1/2013	The modified selenenyl amide, M-hydroxy ebselen, attenuates diabetic nephropathy and diabetes-associated atherosclerosis in ApoE/GPx1 double knockout mice.
12/2010	Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse.
6/2009	Site-specific antiatherogenic effect of the antioxidant ebselen in the diabetic apolipoprotein E-deficient mouse.
4/2007	Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nada Stefanovic Research Topics

Disease

11	Atherosclerosis 01/2021 - 06/2006
6	Inflammation (Inflammations) 01/2021 - 12/2010
3	Diabetic Nephropathies (Diabetic Nephropathy) 09/2014 - 09/2005
2	Hyperglycemia 01/2017 - 12/2010
2	Cardiovascular Diseases (Cardiovascular Disease) 04/2016 - 12/2015
2	Fibrosis (Cirrhosis) 12/2010 - 09/2005
1	Vascular Diseases (Vascular Disease) 01/2021
1	Coronary Artery Disease (Coronary Atherosclerosis) 12/2015
1	Atherosclerotic Plaque (Atheroma) 12/2015
1	Disease Progression 06/2013
1	Sepsis (Septicemia) 06/2013
1	Vascular System Injuries 01/2013
1	Retinopathy of Prematurity (Retrolental Fibroplasia) 01/2013
1	Gliosis 01/2013
1	Hyperlipidemias (Hyperlipidemia) 12/2010
1	Diabetes Complications 12/2010
1	Hypertrophy 09/2005
1	Sclerosis 09/2005

Drug/Important Bio-Agent (IBA)

9	AntioxidantsIBA 01/2017 - 09/2005
6	Apolipoproteins E (ApoE)IBA 11/2016 - 04/2007
6	Glutathione (Reduced Glutathione)IBA 04/2016 - 09/2005
4	EnzymesIBA 04/2016 - 09/2005
3	ApolipoproteinsIBA 01/2021 - 04/2007
3	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2016 - 09/2005
3	ebselenIBA 01/2013 - 06/2009
2	Streptozocin (Streptozotocin)FDA Link 01/2021 - 09/2005
2	PlasmalogensIBA 11/2016 - 12/2015
1	NLR ProteinsIBA 01/2021
1	InflammasomesIBA 01/2021
1	N- (1,2,3,5,6,7- hexahydro- S- indacen- 4- ylcarbamoyl)- 4- (2- hydroxy- 2- propanyl)- 2- furansulfonamideIBA 01/2021
1	CytokinesIBA 01/2021
1	Insulin (Novolin)FDA Link 01/2017
1	batyl alcoholIBA 12/2015
1	Phospholipids (Phosphatides)FDA LinkGeneric 12/2015
1	Nitric Oxide Synthase (NO Synthase)IBA 11/2015
1	Peptides (Polypeptides)IBA 11/2015
1	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 11/2015
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2014
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 09/2014
1	bardoxolone methylIBA 09/2014
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 09/2014
1	6-chloropenicillanic acid S-sulfoxideIBA 06/2013
1	Retinaldehyde (Retinal)IBA 01/2013
1	AmidesIBA 01/2013
1	Proteins (Proteins, Gene)FDA Link 12/2010
1	VimentinIBA 09/2005
1	Transforming Growth Factor beta (TGF-beta)IBA 09/2005
1	CollagenIBA 09/2005
1	IsoprostanesIBA 09/2005

Therapy/Procedure

1	Therapeutics 12/2010